{
    "clinical_study": {
        "@rank": "164902", 
        "arm_group": [
            {
                "arm_group_label": "Sequence A", 
                "arm_group_type": "Other", 
                "description": "Phase 1 (3-week run-in period): Marevan\u00ae\nPhase 2 (4 weeks): Marevan\u00ae\nPhase 3 (4 weeks): generic warfarin #1\nPhase 4 (4 weeks): generic warfarin #2"
            }, 
            {
                "arm_group_label": "Sequence B", 
                "arm_group_type": "Other", 
                "description": "Phase 1 (3-week run-in period): generic warfarin #1\nPhase 2 (4 weeks): generic warfarin #1\nPhase 3 (4 weeks): Marevan\u00ae\nPhase 4 (4 weeks): generic warfarin #2"
            }, 
            {
                "arm_group_label": "Sequence C", 
                "arm_group_type": "Other", 
                "description": "Phase 1 (3-week run-in period): generic warfarin #1\nPhase 2 (4 weeks): generic warfarin #1\nPhase 3 (4 weeks): generic warfarin #2\nPhase 4 (4 weeks): Marevan\u00ae"
            }, 
            {
                "arm_group_label": "Sequence D", 
                "arm_group_type": "Other", 
                "description": "Phase 1 (3-week run-in period): Marevan\u00ae\nPhase 2 (4 weeks): Marevan\u00ae\nPhase 3 (4 weeks): generic warfarin #2\nPhase 4 (4 weeks): generic warfarin #1"
            }, 
            {
                "arm_group_label": "Sequence E", 
                "arm_group_type": "Other", 
                "description": "Phase 1 (3-week run-in period): generic warfarin #2\nPhase 2 (4 weeks): generic warfarin #2\nPhase 3 (4 weeks): Marevan\u00ae\nPhase 4 (4 weeks): generic warfarin #1"
            }, 
            {
                "arm_group_label": "Sequence F", 
                "arm_group_type": "Other", 
                "description": "Phase 1 (3-week run-in period): generic warfarin #2\nPhase 2 (4 weeks): generic warfarin #2\nPhase 3 (4 weeks): generic warfarin #1\nPhase 4 (4 weeks): Marevan\u00ae"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess whether the switch from branded to generic warfarin\n      or between different generic warfarin tablets may cause fluctuation in the results of\n      coagulation tests (International Normalized Rate, acronym INR) in patients, thus\n      predisposing them to unnecessary risks."
        }, 
        "brief_title": "Therapeutic Equivalence Between Branded and Generic Warfarin Tablets in Brazil", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "detailed_description": {
            "textblock": "1. Objective\n\n           1.1 Main Objective\n\n           We aim to determine, through mean INR change from baseline results, whether there is\n           therapeutic equivalency between the branded warfarin sodium (Marevan\u00ae) and the generic\n           formulations in atrial fibrillation patients in Brazil.\n\n           1.2 Specific Objective\n\n           In order to achieve the objective, we aim to assess with each warfarin formulation:\n\n             -  mean INR;\n\n             -  mean prothrombin time (PT);\n\n             -  the incidence of thromboembolic events;\n\n             -  the incidence of bleeding;\n\n             -  the time in therapeutic range;\n\n             -  and compliance with treatment.\n\n        2. Hypothesis\n\n           Our hypothesis is that the mean INR of patients when using the generic tablets of\n           warfarin sodium does not differ by more than 0.49 (two-sided) from the mean INR\n           obtained when using the branded formulation, thereby demonstrating therapeutic\n           equivalence.\n\n        3. Type of Study\n\n           This study is a crossover randomized controlled equivalence trial. It comprises four\n           phases, being the first one a three-week long run-in period and the following phases\n           each four-week long. Patients will use a different warfarin sodium tablet formulation\n           in each one of the phases 2, 3 and 4: either the branded Marevan\u00ae (Uni\u00e3o\n           Qu\u00edmica/Farmoqu\u00edmica, Brasil), or two generic drugs, (manufactured by Uni\u00e3o Qu\u00edmica\n           Farmac\u00eautica Nacional S/A or Laborat\u00f3rio Teuto Brasileiro S/A, Brasil) purchased from\n           Brazilian drugstores (not directly from the manufacturer). Every patient will use each\n           one of the three formulations in a previously determined sequence (A, B, C, D, E or F)\n           to which he was assigned by randomization.\n\n           Since patients included in the study will already be using warfarin and it is not\n           ethically acceptable to interrupt this treatment, we planned a run-in period equivalent\n           to seven warfarin half-lives, long enough to washout any previous warfarin treatment.\n           Then, in this first phase, patients will start treatment with the same warfarin\n           formulation that will be used in the second phase thus avoiding the carry-over effect.\n           Also, data derived from this first phase will not be considered in the final analysis.\n           This period will also be used to select patients compliant with treatment, accepting\n           those with at least 70% TTR.\n\n        4. Methods\n\n           An independent investigator (initials TFCP) will use a computer random number generator\n           to allocate patients to one of the six sequences of treatment. The principal\n           investigator (initials CGF) will separate, repack and dispense drugs for patients in\n           opaque drug containers of identical appearance. This process will be based on the\n           initials of the patient and the alphanumeric code, maintaining the allocation\n           concealment since TFCP will be responsible for assigning to the repacked drugs the\n           patient initials and the alphanumeric code correlated with the formulation of warfarin\n           utilized. TFCP will also be accountable to conceal the allocation until the statistical\n           analysis at the end of the study. Due to the features of the drug containers,\n           physicians and the principal investigator (that assess patients and collect outcomes)\n           will be blinded. Patients may not be blinded depending on the appearance of the\n           manufactured tablets, but the main outcome will be a laboratory result (INR).\n\n        5. Sample Size\n\n           Forty-eight patients (eight in each group) is the minimum necessary number of\n           individuals to detect a clinically significant fluctuation of 0.49 in the mean INR,\n           with a 90% power at a 5% level of significance, if one were present. This sample size\n           was estimated considering the Pocock's statistical method for quantitative outcomes and\n           an achieved mean INR and standard deviation with the branded warfarin of 2.45 and 0.29\n           respectively. To compensate possible withdrawals or exclusions of patients we plan to\n           recruit 60 patients (ten in each group).\n\n        6. Statistical Analysis\n\n           For the INR and PT outcomes paired t-test will be used at a two-sided 5% level of\n           significance. These analysis will be per protocol, i.e., data from patients that during\n           the follow-up start treatment with substances or drugs that interact either in a\n           moderate or major way or are contraindicated when used with warfarin (Annex I) will be\n           excluded.\n\n           Binary outcomes (TTR, thromboembolic or bleeding events) will be analysed by Mcnemar\n           test at a 5% level of significance using intention to treat i.e. considering missing\n           data as adverse outcomes. In this case sensibility analysis will be conducted.\n           Exploratory analysis for subgroup of patients are not intended.\n\n        7. Annex I (obtained from the online database Micromedex \u00ae 2.0 in September 13, 2013)\n\n             -  abciximab\n\n             -  acarbose\n\n             -  acemetacin\n\n             -  acenocoumarol\n\n             -  acetaminophen\n\n             -  agrimony\n\n             -  alclofenac\n\n             -  alefacept\n\n             -  allopurinol\n\n             -  aloe\n\n             -  aminoglutethimide\n\n             -  amiodarone\n\n             -  amitriptyline\n\n             -  amobarbital sodium\n\n             -  amoxapine\n\n             -  amoxicillin\n\n             -  ampicillin trihydrate\n\n             -  amprenavir\n\n             -  angelica\n\n             -  anise\n\n             -  antithyroid agents\n\n             -  apazone\n\n             -  apixaban\n\n             -  aprepitant\n\n             -  aprobarbital\n\n             -  argatroban\n\n             -  armodafinil\n\n             -  arnica\n\n             -  asafetida\n\n             -  aspirin\n\n             -  astragalus\n\n             -  atazanavir\n\n             -  atenolol\n\n             -  atovaquone\n\n             -  avocado\n\n             -  azathioprine\n\n             -  azithromycin\n\n             -  bee pollen\n\n             -  benoxaprofen\n\n             -  benzbromarone\n\n             -  betamethasone\n\n             -  bicalutamide\n\n             -  bilberry\n\n             -  bismuth subsalicylate\n\n             -  bivalirudin\n\n             -  black cohosh extract\n\n             -  black currant\n\n             -  black haw\n\n             -  black tea\n\n             -  bladderwrack\n\n             -  boceprevir\n\n             -  bogbean\n\n             -  boldo\n\n             -  borage\n\n             -  bosentan\n\n             -  bromelain\n\n             -  bromfenac\n\n             -  buchu\n\n             -  bufexamac\n\n             -  butabarbital\n\n             -  butalbital\n\n             -  capecitabine\n\n             -  capsaicin\n\n             -  carbamazepine\n\n             -  carbenicillin disodium\n\n             -  carboplatin\n\n             -  carprofen\n\n             -  cassia\n\n             -  cat's claw\n\n             -  cefadroxil\n\n             -  cefamandole\n\n             -  cefazolin sodium\n\n             -  cefdinir\n\n             -  cefepime\n\n             -  cefixime\n\n             -  cefoperazone\n\n             -  cefotaxime\n\n             -  cefotetan\n\n             -  cefpodoxime\n\n             -  ceftazidime\n\n             -  ceftibuten\n\n             -  ceftizoxime\n\n             -  ceftriaxone\n\n             -  celecoxib\n\n             -  celery\n\n             -  cephalexin\n\n             -  cephalothin sodium\n\n             -  cephapirin\n\n             -  chamomile\n\n             -  chaparral\n\n             -  chitosan\n\n             -  chloral hydrate\n\n             -  chloramphenicol\n\n             -  chlordiazepoxide\n\n             -  chlorotrianisene\n\n             -  chlorpromazine hydrochloride\n\n             -  cholestyramine\n\n             -  chondroitin\n\n             -  cimetidine\n\n             -  cinchona\n\n             -  ciprofloxacin\n\n             -  cisapride monohydrate\n\n             -  cisplatin\n\n             -  citalopram\n\n             -  clarithromycin\n\n             -  clofibrate\n\n             -  clomipramine hydrochloride\n\n             -  clopidogrel\n\n             -  clove\n\n             -  clove oil\n\n             -  cloxacillin benzathine\n\n             -  coenzyme Q10\n\n             -  colesevelam\n\n             -  contraceptives, combination\n\n             -  cortisone\n\n             -  cranberry juice\n\n             -  curcumin\n\n             -  cyclophosphamide\n\n             -  cyclosporine, modified\n\n             -  dabigatran\n\n             -  dabrafenib\n\n             -  dalteparin\n\n             -  danaparoid\n\n             -  danazol\n\n             -  dandelion\n\n             -  dapsone\n\n             -  darunavir\n\n             -  deferasirox\n\n             -  delavirdine\n\n             -  demeclocycline\n\n             -  desipramine\n\n             -  desvenlafaxine\n\n             -  devil's claw\n\n             -  dexamethasone\n\n             -  dexlansoprazole\n\n             -  dexmethylphenidate\n\n             -  diazoxide\n\n             -  diclofenac\n\n             -  dicloxacillin\n\n             -  diethylstilbestrol\n\n             -  diflunisal\n\n             -  dipyridamole\n\n             -  dipyrone\n\n             -  disopyramide\n\n             -  disulfiram\n\n             -  dong quai\n\n             -  dothiepin\n\n             -  doxepin\n\n             -  doxorubicin\n\n             -  doxycycline calcium\n\n             -  dronedarone\n\n             -  droxicam\n\n             -  duloxetine\n\n             -  enoxacin\n\n             -  enoxaparin\n\n             -  enteral nutrition\n\n             -  enzalutamide\n\n             -  eptifibatide\n\n             -  erlotinib\n\n             -  erythromycin acistrate\n\n             -  escitalopram\n\n             -  esomeprazole\n\n             -  eterobarb\n\n             -  ethacrynic acid\n\n             -  ethanol\n\n             -  ethchlorvynol\n\n             -  ethotoin\n\n             -  etodolac\n\n             -  etoposide\n\n             -  etravirine\n\n             -  etretinate\n\n             -  evening primrose oil\n\n             -  exenatide\n\n             -  ezetimibe\n\n             -  felbamate\n\n             -  fenbufen\n\n             -  fenofibrate\n\n             -  fenofibric acid\n\n             -  fenoprofen\n\n             -  fenugreek\n\n             -  feverfew\n\n             -  fish oil\n\n             -  floctafenine\n\n             -  flosequinan\n\n             -  fluconazole\n\n             -  fludrocortisone acetate\n\n             -  flufenamic acid\n\n             -  fluorouracil\n\n             -  fluoxetine\n\n             -  fluoxymesterone\n\n             -  flurbiprofen\n\n             -  flutamide\n\n             -  fluvastatin\n\n             -  fluvoxamine\n\n             -  fosamprenavir\n\n             -  fosaprepitant\n\n             -  garlic\n\n             -  gatifloxacin\n\n             -  gefitinib\n\n             -  gemcitabine\n\n             -  gemfibrozil\n\n             -  gemifloxacin\n\n             -  ginger\n\n             -  ginkgo\n\n             -  ginseng, siberian\n\n             -  glimepiride\n\n             -  glipizide\n\n             -  glucagon\n\n             -  glucosamine\n\n             -  glutethimide\n\n             -  glyburide\n\n             -  goldenseal\n\n             -  green tea\n\n             -  griseofulvin\n\n             -  guggul\n\n             -  halothane\n\n             -  heparin calcium\n\n             -  heptabarbital\n\n             -  hexobarbital sodium\n\n             -  high protein food\n\n             -  horse chestnut\n\n             -  horseradish\n\n             -  hydrocortisone\n\n             -  ibritumomab\n\n             -  ibuprofen\n\n             -  ifosfamide\n\n             -  imatinib\n\n             -  imipramine hydrochloride\n\n             -  indomethacin\n\n             -  indoprofen\n\n             -  infliximab\n\n             -  influenza virus vaccine\n\n             -  ipriflavone\n\n             -  isoniazid\n\n             -  isoxicam\n\n             -  itraconazole\n\n             -  ivacaftor\n\n             -  ivermectin\n\n             -  kava\n\n             -  ketoconazole\n\n             -  ketoprofen\n\n             -  ketorolac tromethamine\n\n             -  lactulose\n\n             -  lansoprazole\n\n             -  leflunomide\n\n             -  lepirudin\n\n             -  levamisole\n\n             -  levofloxacin\n\n             -  licorice\n\n             -  lopinavir\n\n             -  lornoxicam\n\n             -  lovastatin\n\n             -  lycium\n\n             -  marijuana\n\n             -  meadowsweet\n\n             -  mechlorethamine\n\n             -  meclofenamate\n\n             -  mefenamic acid\n\n             -  melatonin\n\n             -  meloxicam\n\n             -  menthol\n\n             -  mephobarbital\n\n             -  mercaptopurine\n\n             -  mesalamine\n\n             -  mesna\n\n             -  methandrostenolone\n\n             -  methicillin\n\n             -  methotrexate\n\n             -  methyl salicylate\n\n             -  methylphenidate\n\n             -  methylprednisolone acetate\n\n             -  methyltestosterone\n\n             -  metronidazole\n\n             -  miconazole\n\n             -  mifepristone\n\n             -  milnacipran\n\n             -  minocycline hydrochloride\n\n             -  mistletoe\n\n             -  mitotane\n\n             -  moricizine hydrochloride\n\n             -  motherwort\n\n             -  moxalactam\n\n             -  moxifloxacin\n\n             -  nabumetone\n\n             -  nafcillin\n\n             -  nalidixic acid\n\n             -  nandrolone\n\n             -  naproxen\n\n             -  nelfinavir\n\n             -  neomycin\n\n             -  nettle extract\n\n             -  nevirapine\n\n             -  niacin\n\n             -  nilutamide\n\n             -  nimesulide\n\n             -  norfloxacin\n\n             -  nortriptyline hydrochloride\n\n             -  noscapine\n\n             -  ofloxacin\n\n             -  omega-3-acid ethyl esters\n\n             -  omeprazole\n\n             -  onion oil\n\n             -  orlistat\n\n             -  oseltamivir\n\n             -  oxacillin\n\n             -  oxandrolone\n\n             -  oxaprozin\n\n             -  oxymetholone\n\n             -  oxyphenbutazone\n\n             -  oxytetracycline\n\n             -  pantoprazole\n\n             -  papaya\n\n             -  paramethasone\n\n             -  paroxetine\n\n             -  parsley\n\n             -  passionflower\n\n             -  pau d'arco\n\n             -  penicillin G\n\n             -  penicillin V benzathine\n\n             -  pentosan polysulfate sodium\n\n             -  pentoxifylline\n\n             -  phenindione\n\n             -  phenobarbital\n\n             -  phenprocoumon\n\n             -  phenylbutazone\n\n             -  phenytoin\n\n             -  phytonadione\n\n             -  piperacillin\n\n             -  piracetam\n\n             -  pirazolac\n\n             -  piroxicam\n\n             -  pirprofen\n\n             -  policosanol\n\n             -  pomegranate\n\n             -  poplar\n\n             -  posaconazole\n\n             -  prasugrel\n\n             -  prednisolone\n\n             -  prednisone\n\n             -  prickly ash\n\n             -  primidone\n\n             -  procarbazine\n\n             -  proguanil\n\n             -  propafenone hydrochloride\n\n             -  propoxyphene\n\n             -  propranolol\n\n             -  propyphenazone\n\n             -  proquazone\n\n             -  protriptyline\n\n             -  pumpkin seed\n\n             -  quassia\n\n             -  quetiapine\n\n             -  quinestrol\n\n             -  quinidine\n\n             -  quinine\n\n             -  rabeprazole sodium\n\n             -  raloxifene\n\n             -  ranitidine\n\n             -  red clover\n\n             -  rifabutin\n\n             -  rifampin\n\n             -  rifapentine\n\n             -  rifaximin\n\n             -  rilonacept\n\n             -  ritonavir\n\n             -  rivaroxaban\n\n             -  rofecoxib\n\n             -  romidepsin\n\n             -  ropinirole\n\n             -  rosuvastatin\n\n             -  roxithromycin\n\n             -  salicylates\n\n             -  saquinavir\n\n             -  sarsaparilla\n\n             -  saw palmetto extract\n\n             -  secobarbital\n\n             -  senega\n\n             -  sertraline\n\n             -  simvastatin\n\n             -  sitaxsentan\n\n             -  skullcap\n\n             -  sorafenib\n\n             -  soybean\n\n             -  spironolactone\n\n             -  st john's wort\n\n             -  stanozolol\n\n             -  sucralfate\n\n             -  sulfamethoxazole\n\n             -  sulfasalazine\n\n             -  sulfinpyrazone\n\n             -  sulfisoxazole\n\n             -  sulindac\n\n             -  sulofenur\n\n             -  suprofen\n\n             -  sweet woodruff\n\n             -  tamarind\n\n             -  tamoxifen\n\n             -  tan shen\n\n             -  teduglutide\n\n             -  telaprevir\n\n             -  telithromycin\n\n             -  tenidap sodium\n\n             -  tenoxicam\n\n             -  terbinafine\n\n             -  teriflunomide\n\n             -  testosterone\n\n             -  tetracycline\n\n             -  thyroid hormones\n\n             -  tiaprofenic acid\n\n             -  tibolone\n\n             -  ticarcillin\n\n             -  ticlopidine\n\n             -  tigecycline\n\n             -  tinidazole\n\n             -  tinzaparin\n\n             -  tirofiban\n\n             -  tocilizumab\n\n             -  tolmetin\n\n             -  tolterodine tartrate\n\n             -  tonka\n\n             -  toremifene citrate\n\n             -  torsemide\n\n             -  tramadol\n\n             -  trastuzumab\n\n             -  treprostinil\n\n             -  triamcinolone acetonide\n\n             -  trimipramine\n\n             -  valdecoxib\n\n             -  valproic acid\n\n             -  vancomycin\n\n             -  vemurafenib\n\n             -  venlafaxine\n\n             -  vilazodone\n\n             -  vincristine\n\n             -  vindesine\n\n             -  vitamin A\n\n             -  vitamin E\n\n             -  vitamin K\n\n             -  voriconazole\n\n             -  vorinostat\n\n             -  wild lettuce\n\n             -  willow\n\n             -  wintergreen\n\n             -  yarrow\n\n             -  zafirlukast\n\n             -  zileuton\n\n             -  zomepirac sodium\n\n             -  zotepine"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diagnosis of nonvalvular atrial fibrillation by electrocardiogram and\n             echocardiography;\n\n          -  CHA2DS2VASc score equal to or greater than 1;\n\n          -  already in use of warfarin;\n\n          -  signing of Informed Consent Form.\n\n        Exclusion Criteria:\n\n          -  patients with contraindications to the use of anticoagulants (patients either  taking\n             other anticoagulants, or with active bleeding, or hypersensitive to warfarin or with\n             ulcers);\n\n          -  women of childbearing age, pregnant or breastfeeding;\n\n          -  patients with thrombocytopenia;\n\n          -  patients with hepatic or renal impairment;\n\n          -  patients with a history of bleeding episodes due to congenital deficiency of\n             coagulation factors;\n\n          -  patients enrolled in another trial;\n\n          -  patients not achieving at least 70% TTR in the run-in period\n\n          -  patients initiating treatment with drugs with either moderate or major interactions\n             or which are contraindicated when used concomitantly with warfarin, according to our\n             list (Annex I)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02017197", 
            "org_study_id": "RCT 01 GW", 
            "secondary_id": "U1111-1155-4833"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence A", 
                    "Sequence B", 
                    "Sequence C", 
                    "Sequence D", 
                    "Sequence E", 
                    "Sequence F"
                ], 
                "description": "Branded warfarin sodium tablets (manufacturer Uni\u00e3o Qu\u00edmica Farmac\u00eautica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.", 
                "intervention_name": "Marevan\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "warfarin"
            }, 
            {
                "arm_group_label": [
                    "Sequence A", 
                    "Sequence B", 
                    "Sequence C", 
                    "Sequence D", 
                    "Sequence E", 
                    "Sequence F"
                ], 
                "description": "Generic warfarin sodium tablets, manufacturer (Uni\u00e3o Qu\u00edmica Farmac\u00eautica Nacional S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.", 
                "intervention_name": "generic warfarin #1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence A", 
                    "Sequence B", 
                    "Sequence C", 
                    "Sequence D", 
                    "Sequence E", 
                    "Sequence F"
                ], 
                "description": "Generic warfarin sodium tablets, manufacturer (Laborat\u00f3rio Teuto Brasileiro S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.", 
                "intervention_name": "generic warfarin #2", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Warfarin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Therapeutic Equivalency", 
            "Warfarin", 
            "Drugs, Generic", 
            "Anticoagulants", 
            "Anticoagulants [Pharmacological Action]", 
            "Coumarins"
        ], 
        "lastchanged_date": "May 24, 2014", 
        "location": {
            "contact": {
                "email": "carolina.freitas@unifesp.br", 
                "last_name": "Carolina Gomes Freitas, BPharm", 
                "phone": "+551155752970"
            }, 
            "facility": {
                "address": {
                    "city": "S\u00e3o Paulo", 
                    "country": "Brazil", 
                    "zip": "04024-002"
                }, 
                "name": "Hospital S\u00e3o Paulo/Hospital Universit\u00e1rio da UNIFESP (University Hospital of UNIFESP)"
            }, 
            "investigator": {
                "last_name": "Carolina Gomes Freitas, PharmD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "6", 
        "official_title": "Therapeutic Equivalence Between Branded and Generic Warfarin Sodium Tablets in Adult Patients With Atrial Fibrillation in Brazil - Crossover Randomized Controlled Equivalence Trial", 
        "other_outcome": {
            "description": "Performed by counting of returned pills", 
            "measure": "Compliance with treatment", 
            "safety_issue": "No", 
            "time_frame": "Monthly (from the beginning of treatment up to week 15)."
        }, 
        "overall_contact": {
            "email": "carolina.freitas@unifesp.br", 
            "last_name": "Carolina Gomes Freitas, PharmD", 
            "phone": "+551155764203"
        }, 
        "overall_official": {
            "affiliation": "Federal University of Sao Paulo (UNIFESP)", 
            "last_name": "Carolina Gomes Freitas, PharmD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "INR: International normalized ratio. The final analysis will not consider data from the run-in period (phase 1). INR will be assessed twice a month during the 15 weeks of study.\nMean INR for each patient will be measured while using each generic formulation of warfarin; the baseline will be the mean INR during the use of the branded warfarin (Marevan\u00ae). Outcome will then be the mean difference between these two measurements.", 
            "measure": "Mean change in INR with each generic formulation", 
            "safety_issue": "Yes", 
            "time_frame": "After four weeks with each formulation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02017197"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Federal University of S\u00e3o Paulo", 
            "investigator_full_name": "Carolina Gomes Freitas", 
            "investigator_title": "Graduate student (masters)", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "PT: prothrombin time. The final analysis will not consider data from the run-in period (phase 1). PT will be assessed twice a month during the 15 weeks of study.\nMean PT for each patient will be measured while using each generic formulation of warfarin; the baseline will be the mean PT during the use of the branded warfarin (Marevan\u00ae). Outcome will then be the mean difference between these two measurements.", 
                "measure": "Mean change in PT with each generic formulation", 
                "safety_issue": "Yes", 
                "time_frame": "After four weeks with each formulation"
            }, 
            {
                "description": "Includes ischemic stroke (differential diagnosis with hemorrhagic stroke by tomography) and thromboembolism of viscera or extremities (diagnosed by acute symptoms and relevant diagnostic tests). The final analysis will not consider data from the run-in period (phase 1).", 
                "measure": "Incidence of thromboembolic events", 
                "safety_issue": "No", 
                "time_frame": "At weeks 7, 11 and 15 (i.e. at the end of phases 2, 3 and 4)"
            }, 
            {
                "description": "TTR calculated by Rosendaal Method also known as linear interpolation method. The final analysis will not consider data from the run-in period (phase 1).", 
                "measure": "Time in therapeutic range (TTR)", 
                "safety_issue": "Yes", 
                "time_frame": "At weeks 7, 11 and 15 (i.e. at the end of phases 2, 3 and 4)"
            }, 
            {
                "description": "Classified as major or minor bleeding events.\nMajor: intracranial hemorrhage, fatal bleeding, bleeding resulting in hemoglobin  loss equal to or greater than 2.0 g / L, hemorrhage requiring transfusion, bleeding in sensitive areas such as the retina or pericardium.\nMinor: all other bleeding.\nThe final analysis will not consider data from the run-in period (phase 1).", 
                "measure": "Incidence of bleeding events", 
                "safety_issue": "Yes", 
                "time_frame": "At weeks 7, 11 and 15 (i.e. at the end of phases 2, 3 and 4)"
            }
        ], 
        "source": "Federal University of S\u00e3o Paulo", 
        "sponsors": {
            "collaborator": {
                "agency": "Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Federal University of S\u00e3o Paulo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}